11.9 C
New York
Wednesday, March 22, 2023

The Question Is Whether To Buy Or Not To Buy RAPT Therapeutics Inc. (NASDAQ: RAPT)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for RAPT Therapeutics Inc. (RAPT) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.98, or 4.97%, to $20.68. The RAPT Therapeutics Inc. has recorded 53,113 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Stocks Info

RAPT Therapeutics Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $19.70 and fluctuated between $25.31 as its day high and $17.82 as its day low. The current market capitalization of RAPT Therapeutics Inc. is $794.70M. A total of 2.89 million shares were traded on the day, compared to an average of 437.35K shares.

Insider Activity

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, RAPT has seen 2 BUY and 4 SELL insider trades, representing the acquisition of 2,422 and the disposition of 15,742 shares. Over the last 12 months, there were 36 BUYs and 12 SELLs from insiders. Insiders purchased 2,580,428 shares during that period but sold 38,609.

In the most recent transaction, HO WILLIAM sold 5,000 shares of RAPT for 29.62 per share on Mar 07. After the transaction, the Chief Medical Officer now owns 25,532 company shares. In a previous transaction on Jan 24, HO WILLIAM sold 5,000 shares at 30.00 per share. RAPT shares that Chief Medical Officer owns now total 30,072.

Among the insiders who sold shares, HO WILLIAM disposed of 5,000 shares on Jan 19 at a per-share price of $25.56. This resulted in the Chief Medical Officer holding 35,072 shares of RAPT after the transaction. In another insider transaction, Brockstedt Dirk G. sold 742 shares at $21.97 per share on Jan 05. Company shares held by the Chief Scientific Officer now total 19,070.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for RAPT in the last 3 months, the mean price target is $46.75 with high estimates of $55.00 and low estimates of $33.00. In terms of 52-week highs and lows, RAPT has a high of $32.45 and a low of $9.85.

As of this writing, RAPT has an earnings estimate of -$0.66 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of -$0.57 per share and a lower estimate of -$0.72. The company reported an EPS of -$0.62 in the last quarter, which was 17.30% higher than expectations of -$0.75.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 8 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RAPT is Overweight with a score of 5.00. A total of 7 analysts rated the stock as Buy while 1 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles